Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.38 SEK | -2.59% | -7.65% | -14.32% |
Mar. 27 | Enzymatica AB Announces Composition of Nomination Committee | CI |
Mar. 11 | Enzymatica Obtains CE Marking for ColdZyme Mouth Spray | MT |
Sales 2024 * | 7.14M 78.73M | Sales 2025 * | 13.98M 154M | Capitalization | 53.64M 592M |
---|---|---|---|---|---|
Net income 2024 * | -3M -33.08M | Net income 2025 * | - 0 | EV / Sales 2024 * | 7.79 x |
Net Debt 2024 * | 2.01M 22.14M | Net cash position 2025 * | 2.05M 22.63M | EV / Sales 2025 * | 3.69 x |
P/E ratio 2024 * |
-18.2
x | P/E ratio 2025 * |
-38.7
x | Employees | 18 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 36.72% |
1 day | -2.59% | ||
1 week | -7.65% | ||
Current month | +4.00% | ||
1 month | +9.39% | ||
3 months | -5.98% | ||
6 months | +6.29% | ||
Current year | -14.32% |
Managers | Title | Age | Since |
---|---|---|---|
Ulf Thomas Blom
FOU | Founder | 59 | 06-12-31 |
Claus Egstrand
CEO | Chief Executive Officer | 63 | 17-07-17 |
Director of Finance/CFO | 55 | 17-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bengt Baron
CHM | Chairman | 62 | 16-12-18 |
Director/Board Member | 56 | 16-02-14 | |
Director/Board Member | 57 | 21-04-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 3.38 | -2.59% | 86,653 |
24-04-17 | 3.47 | -2.25% | 69,420 |
24-04-16 | 3.55 | -1.93% | 54,356 |
24-04-15 | 3.62 | -4.74% | 32,608 |
24-04-12 | 3.8 | +3.83% | 48,627 |
Delayed Quote Nasdaq Stockholm, April 18, 2024 at 11:18 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-14.32% | 54.73M | |
+27.97% | 676B | |
+23.58% | 554B | |
-7.02% | 349B | |
+14.85% | 318B | |
+6.25% | 291B | |
+2.96% | 210B | |
-0.41% | 204B | |
-10.02% | 194B | |
-11.81% | 144B |
- Stock Market
- Equities
- ENZY Stock